Type-2 biomarkers and related cytokines , lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 (-0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV 1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.
Introduction
The effect of high-dose oral corticosteroids in OCS-dependent asthmatics is currently unknown. This group is important as they represent a large proportion of the severe asthma population, are patients with multiple corticosteroid-associated morbidities, and drive much of the healthcare cost of asthma. 1 Type-2 biomarkers are used to guide treatment for novel biologic therapies, making it important to understand the longitudinal stability of their profile following high-dose OCS. The aims of this study were to examine the trajectory of the type-2 biomarker profile in severe OCSdependent asthmatics after additional high-dose OCS.
Methods
Participants aged between 12 and 75 with well characterised severe uncontrolled asthma were recruited from UK Severe Registry centres between July 2013 and February 2014. All patients were adherent with a maintenance dose of at least 10mg prednisolone for at least six months prior to study initiation based on prednisolone/cortisol levels. Full details of study inclusion criteria are given in the online supplement. The study received Ethical Approval from National Research Ethics Service East of England (Ref: 13/EE/0099) and was registered on ClincalTrials.Gov (https://clinicaltrials.gov/ct2/show/NCT01948401).
Subjects were offered a 7-day OCS escalation (0.5mg/kg) and invited to attend four follow-up visits 1 (visit 2), 32 (visit 3), 60 (visit 4) and 88 (visit 5) days post-intervention. Patient outcomes including type-2 biomarkers (blood eosinophils, FeNO, serum periostin), cytokines (serum IL-5, IL-13), spirometry (FEV 1 , FVC), and patient-reported symptoms (ACQ-7) were collected at baseline and during follow-up visits (see tables e1, e2 online supplement). Patients receiving additional rescue OCS for an asthma exacerbation during follow-up were excluded from future study visits.
Descriptive data is presented using the mean (SD) or median (IQR). For normally distributed variables mean change from baseline was calculated for each follow-up visit, and paired t-tests used to formally test for differences. For non-normally distributed variables, median difference from baseline were calculated (with bootstrapped 95% confidence intervals), and the Wilcoxon signedrank test used to test for differences. We conducted separate short-term (visit, visit 2 and visit 3) and long-term (all study visits) analysis. For each outcome, patients with missing data at baseline, visit 2 or visit 3 where excluded from the short-term analysis. Similarly, patients with missing data at any study visit were excluded from the long-term analysis.
Results
Forty-four subjects were recruited and 17 completed long-term follow-up (6 did not consent to longterm follow-up, 2 did not attend study visits, 19 required rescue steroids; Figure e1 ). Cohort details are given in Table 1 .
In the short-term analysis, there were median decreases of 60 cells/µl (95% CI: 10, 140; p=0.004), 8.4 ng/ml (95% CI: 2.8, 11.6; p<0.001) and 19.0 ppb (95% CI: 4.0, 28.5; p<0.001) between baseline and visit 2 for blood eosinophils, serum periostin and FeNO respectively (Table 2, figure e2). Serum IL-5 and IL-13 concentrations were reduced between baseline and visit 2 by 0.17pg/ml (95% CI: 0.08, 0.28; p=0.002) and 0.15pg/ml (95% CI: 0.03, 0.27; p=0.002) respectively. Blood eosinophils, serum periostin, FeNO and serum IL-5 concentration returned to baseline levels by visit 3 (visit 4 for cytokines), although serum IL-13 was slightly higher (0.07pg/ml; 95% CI: -0.01, 0.33; p=0.028) than baseline (Table 2, figure e2) at this point. FEV 1 (160ml; 95% CI: 50, 270; p=0.005) and FVC (160ml; 95% CI: 40, 280; p=0.009) showed small improvements after high-dose OCS ( Table 2 , figure e2), but were close to baseline by visit 3.
These short-term changes were replicated in patients with complete data to study end, although standard errors were noticeably larger due to a smaller sample size. Each of the study measures was close to baseline by visit 4, and remained relatively stable until visit 5 (Figure 1, table e3 ).
Discussion
Seven days of high-dose OCS treatment significantly reduced type-2 biomarker and related cytokine levels, but was associated with only small improvements in lung function and patient-reported symptoms. In general, all study measures had returned to baseline levels one month postintervention, and remained stable until three months post-intervention.
To our knowledge, this is the first study to investigate the effect of high-dose OCS in severe OCSdependent asthmatics. Our data concurs with studies of broader severe asthma populations which reported significant reductions in blood eosinophils [2] [3] [4] and FeNO 2-4 after high-dose OCS. Changes in serum type-2 cytokine levels have been variably reported. 2 5 Increased FEV 1 2-9 , and improved ACQ scores 3 4 have been reported after high-dose OCS in patients not on maintenance steroids.
Our results suggest that, after rescue steroids, clinicians should wait one month before using type-2 biomarkers to guide treatment in OCS-dependent asthmatics. This is particularly relevant for patients where type-2 biomarkers are used to guide treatment for biologic therapies, where failure to account for recent high-dose OCS could lead to effective therapies being unnecessarily withheld.
The high exacerbation rate observed within our study suggests that the issue of how to interpret type-2 biomarker results in light of recent rescue steroids is commonly faced in routine clinical practice. Our data confirm that high-dose OCS inhibit both the IL-5 and IL-13 pathways, but despite significant reductions in type-2 inflammation, patients had significant residual impaired lung function and high symptoms scores. This suggests that broad targeting of the type-2 cytokine axis may leave significant unmet clinical need.
The study has some potential weaknesses as it is observational and hence open to confounding. The first post-intervention follow-up was one month after the intervention period, therefore a more precise timing of biomarker levels returning to baseline prior to this time-point could not be determined. However, type-2 biomarkers were decreased two weeks after prednisolone treatment for acute exacerbation, suggesting that shorter time periods are unlikely to be sufficient. 10 We necessarily excluded patients who had additional rescue OCS to treat exacerbations during follow-up which reduced the sample size in our long-term analysis and may have hindered generalisability.
In summary, type-2 biomarker and serum cytokine levels are significantly suppressed after high-dose OCS treatment in OCS-dependent asthmatics, but return to baseline levels after one month.
Following rescue steroids, one month is a sufficient time period before using type-2 biomarkers to guide long-term treatment decisions.
Figure Legends
Figure 1: Trajectories of type-2 biomarkers and cytokines, patient reported outcomes (ACQ and AQLQ) and lung function (FEV 1 and FVC) over serial study visits -subjects with missing data at any of the study visit, or who required additional rescue corticosteroids for exacerbation in addition to the high-dose OCS between baseline visit and study 2 were excluded. Data are shown as median or mean difference (with 95% confidence intervals) as appropriate. Table 1 : Baseline characteristics of the study population.
Tables and Figures
Data are shown as median (IQR), mean (SD) or n (%) as appropriate. Figure 1 : Trajectories of type-2 biomarkers and cytokines, patient reported outcomes (ACQ and AQLQ) and lung function (FEV 1 and FVC) over serial study visits -subjects with missing data at any of the study visit, or who required additional rescue corticosteroids for exacerbation in addition to the high-dose OCS between baseline visit and study 2 were excluded. Data are shown as median or mean difference (with 95% confidence intervals) as appropriate. Significant at the 5% (*) or 1% (**) level.
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Study inclusion and exclusion criteria Inclusion Criteria
Patients must meet the following criteria for study entry:
1. Able and willing to provide written informed consent and to comply with the study procedures. 
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry: . Other clinically significant medical disease that is uncontrolled despite treatment or that is likely, in the opinion of the investigator, to require a change in therapy or affect the ability to participate in the study 11. History of alcohol, drug, or chemical abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator 12. Current smoker or former smoker with a smoking history of >15 pack-years A current smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥30 days within the 24 months before the time of informed consent and for whom cotinine testing is positive.
A former smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥30 days in his or her lifetime (as long as the 30-day total did not include the 24 months before the time of informed consent) and for whom cotinine testing is negative. : Trajectories of type-2 biomarkers and cytokines, patient reported outcomes (ACQ-7 and AQLQ) and lung function (FEV 1 and FVC) over serial study visits -subjects with missing data at any short-term visit, or who required additional rescue corticosteroids for exacerbation in addition to the high-dose OCS between baseline visit and study 2 were excluded. Data are shown as median or mean difference (with 95% confidence intervals) as appropriate. 
